Clinical Trials Logo
  1. Home
  2. Hyperlipemia
  3. NCT05432544

Safety and Tolerability of SHR-1918 in Healthy Subjects

Hyperlipemia Clinical Trial

Official title:
A Phase 1, Randomized, Double Blind, Dose-escalation, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Subcutaneous Injection of SHR-1918 Injection in Healthy Subjects

Clinical Trial Summary

The primary objective of this study is to assess the safety and tolerability of SHR-1918 injection in healthy subjects. In addition, this study will provide information on pharmacokinetics and pharmacodynamics of SHR-1918 injection in healthy subjects.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05432544
Study type Interventional
Source Beijing Suncadia Pharmaceuticals Co., Ltd
Contact
Status Active, not recruiting
Phase Phase 1
Start date June 27, 2022
Completion date December 12, 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT04382521 - A Text Message Intervention to Promote Health Behaviors in Cardiac Risk Conditions N/A
Not yet recruiting NCT02593487 - Effect of Rosuvastatin Therapy on HDL2 Level Phase 4
Active, not recruiting NCT02697422 - Veteran Peer Coaches Optimizing and Advancing Cardiac Health N/A
Completed NCT04469673 - A Study to Evaluate the Safety, Tolerability and Efficacy of Multiple Doses of JS002 in Patients With Hyperlipidemia.. Phase 1/Phase 2
Recruiting NCT05912296 - A Single and Multiple Ascending Doses Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RBD7022 Phase 1
Completed NCT03950752 - Effect of Consumption of Bagel Without Palm Oil on Postprandial Lipidemia N/A
Not yet recruiting NCT06229548 - A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2053 Phase 1
Completed NCT05532800 - The Efficacy and Safety of JS002 PFS and AI in Patients With Primary Hypercholesterolemia and Mixed Hyperlipidemia Phase 3
Completed NCT04781114 - The Safety and Efficacy of Multiple-dose of JS002 in Subject With Hyperlipidemia Phase 3
Active, not recruiting NCT04515927 - To Evaluate the Efficacy and Safety of JS002 in HoFH Patients Phase 2